Newsroom
Sorted by: Latest
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Meta Is Back in the AI Race. Muse Wonder Just Ranked #2 for Accounting, According to DualEntry Accounting AI Benchmark
NEW YORK--(BUSINESS WIRE)--Meta's new Muse Wonder model got 83.2% of tasks right on the DualEntry Accounting AI Benchmark, tying for second place among 57 AI models tested. Its predecessor, Muse Spark 1.1, scored 61.4% on the same tasks. Meta released Muse Wonder on October 12 and called it its most capable model to date. On accounting work, it now sits ahead of every OpenAI and Google model on the benchmark and level with Anthropic's Claude Fable 5. Only Grok 4.5 scored higher, at 84.2%. Key r...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
KAST تختار Claire Wells من Kiln لمنصب رئيسة الشؤون القانونية
نيويورك--(BUSINESS WIRE)--اليوم، أعلنت KAST، وهي صاحبة التطبيق العالمي لتحويل الأموال، عن انضمام Claire Wells إلى الشركة كرئيسة للشؤون القانونية.ستتولى Wells قيادة العمليات القانونية العالمية لشركة KAST، وستكون مبادرات الشركة المتعلقة بالامتثال والتنظيم وجمع التبرعات والترخيص ضمن نطاق مسؤوليتها. وتعد Wells قائدة في المجال القانوني ومسؤولة عن الامتثال تتمتع بخبرة عميقة في بناء وتوسيع نطاق الوظائف القانونية والتنظيمية والسياسية في مجالات التكنولوجيا المالية والمدفوعات والأصول الرقمية. ولقد نجحت في...
-
Zumigo Makes the Mobile Phone a Frictionless and Fraud-Aware Anchor of Digital Identity, Checking for SIM Swaps and Takeover Behind Every Silent Login
SAN JOSE, Calif.--(BUSINESS WIRE)--Zumigo announces fraud-aware silent authentication that verifies customers by phone and returns SIM swap signals to help stop account takeover....
-
Quantum Lifecycle Partners' Albuquerque Facility Becomes First in New Mexico to Achieve R2v3 Certification
ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Quantum Lifecycle Partners, formerly known as 2NDGEAR, announced today that its Technology Center in Albuquerque, New Mexico has been awarded R2v3 certification, becoming the first facility in the state of New Mexico to achieve this distinction. The milestone comes shortly after 2NDGEAR officially began operating as Quantum Lifecycle Partners on September 1, 2026. The new name brings the company's U.S. operations under the same brand as Quantum's facilities i...
-
Palmer Square Capital BDC Inc. Announces Third Quarter 2026 Earnings Release and Conference Call
MISSION WOODS, Kan.--(BUSINESS WIRE)--Palmer Square Capital BDC Inc. (NYSE: PSBD) ("Palmer Square" or the "Company"), an externally managed business development company, today announced that it will release its financial results for the third quarter ended September 30, 2026, before the market opens on Wednesday, November 4, 2026. Palmer Square will host a conference call at 1:00 pm ET that day to review its financial performance and conduct a question-and-answer session. To participate in the...
-
Pelage Pharmaceuticals Announces First Patient Dosed in Phase 2/3 AWAKEN Trial of PP405 for Androgenetic Alopecia, the Most Common Form of Hair Loss
LOS ANGELES--(BUSINESS WIRE)--Pelage Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class regenerative treatments for hair loss, today announced that the first patient has been dosed in the Phase 2/3 AWAKEN clinical trial evaluating PP405 in adult men with androgenetic alopecia (AGA), also known as pattern hair loss. The trial initiated on schedule following a positive end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA).“Dosing the first pa...
-
Entegris Declares Quarterly Cash Dividend
BILLERICA, Mass.--(BUSINESS WIRE)--Entegris, Inc. (Nasdaq: ENTG), a leading supplier of critical advanced materials and process solutions for the semiconductor and other high-technology industries, today announced that its board of directors has authorized a quarterly cash dividend of $0.10 per share to be paid on November 18, 2026, to shareholders of record on the close of business on October 28, 2026. ABOUT ENTEGRIS Entegris is a leading supplier of critical advanced materials and process sol...
-
Aeva Announces Date for Third Quarter 2026 Results and Conference Call
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aeva® (Nasdaq: AEVA), a leader in next-generation sensing and perception systems, today announced it will report results for the third quarter 2026 after market close on Wednesday, November 4, 2026. Aeva will host a conference call and webcast to discuss the third quarter 2026 results at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on the same day. Event: Aeva Technologies, Inc. Third Quarter 2026 Results Call Date: Wednesday, November 4, 2026 Time: 2:...